ACKR3 and pulmonary fibrosis: To this effect, various pharmacological CXCR7-agonists have been employed, e.g., cyclic-peptide-(TC14012) [104,105,109], allosteric agonist-(AMD3100) [27,110] ACKR3/CXCR7 specific CCX771 [103], and VUF11207 [76], demonstrating the therapeutic benefits of ACKR3/CXCR7 in functional recovery following myocardial infarction [27,28,76] in impeding pulmonary fibrosis [104], in promoting hepatic regeneration [105] and in retarding atheroprogression [103] (Table 2 and Figure 4).